Shanghai Yizhong Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Yizhong Pharmaceutical Co., Ltd. was established in September 2009 and is a listed enterprise on the Science and Technology Innovation Board (referred to as Shanghai Yizhong, stock code: 688091). The company is committed to the development of innovative drugs and related products, and is a high-tech pharmaceutical enterprise that integrates research and development, production, and commercialization. Shanghai Yizhong currently has a high-quality research and development team with professional backgrounds in pharmaceutical preparations, drug analysis, polymer material synthesis, and other fields. It has advanced production equipment and testing instruments that comply with GMP standards. The company is a pioneer enterprise in innovative drug research and development in China, possessing core key technologies in nanotechnology and the preparation of pharmaceutical polymer excipients. It has unique innovation in the nano drug delivery system, and can use different molecular weight pharmaceutical excipients for classic drugs in clinical applications. Through this technology, the dosage form can be improved, greatly improving its safety and effectiveness, giving it new value and vitality. On October 26, 2021, the core product of the company, "paclitaxel polymer micelles for injection", was approved for listing by the National Drug Administration as a Class 2.2 new drug (an innovative dosage form that has not been listed domestically or internationally). This product is an independently developed innovative dosage form of paclitaxel, and is one of the first batch of projects approved by the National "Major New Drug Creation" Science and Technology Major Special Project "13th Five Year Plan". Based on the research and development of this product, we have 3 invention patents (type: invention patent; patent number: ZL201010217546.4; ZL201110063785.3; ZL201110105540.2), and have successively won multiple honors such as the National Science and Technology Innovation Fund's free funding project and the Shanghai Municipal Science and Technology Commission's scientific and technological achievement transformation and industrialization project. Clinical studies on non-small cell lung cancer have shown that the objective response rate (ORR) and progression free survival (PFS) of paclitaxel micelle tumor therapy have significant clinical advantages compared to other available paclitaxel formulations; With a significant increase in clinical dosage, it has relatively better safety, without the need for any anti allergic pretreatment or the use of special infusion devices before medication, making clinical use convenient; The world's leading technology and clinical efficacy. In the process of continuous development and growth, Shanghai Yizhong has always adhered to the concept of "innovation is the only strategy for enterprise development", established the corporate mission of "innovative development, healthy living beings", formed the core values of "first, only, safe, and forward", and forged the spiritual quality of employees who "do their best". The enterprise will continue to uphold its philosophy, shoulder its mission, adhere to its core values, and meet challenges with unwavering spirit and quality. It is committed to developing a new generation of innovative drugs, providing patients with safe, effective, and affordable high-quality drugs to meet the urgent treatment needs. |
| Headquarter | Shanghai |
| Establish Date | 9/10/2009 |
| Listed Code | 688091.SH |
| Listed Date | 9/9/2021 |
| Chairman | Zhou Jinsong. |
| CEO | Zhou Jinsong. |
| Website | www.yizhongpharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
